Form 8-K - Current report:
SEC Accession No. 0001104659-25-029370
Filing Date
2025-03-28
Accepted
2025-03-28 16:10:31
Documents
13
Period of Report
2025-03-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2510590d1_8k.htm   iXBRL 8-K 25310
  Complete submission text file 0001104659-25-029370.txt   198955

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA acxp-20250325.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE acxp-20250325_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acxp-20250325_pre.xml EX-101.PRE 22365
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2510590d1_8k_htm.xml XML 3685
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40536 | Film No.: 25786086
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)